Sutro Biopharma (STRO) & Its Peers Head-To-Head Review

Sutro Biopharma (NASDAQ: STRO) is one of 114 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Sutro Biopharma to related businesses based on the strength of its analyst recommendations, earnings, valuation, risk, dividends, profitability and institutional ownership.

Valuation and Earnings

This table compares Sutro Biopharma and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Sutro Biopharma $38.42 million -$35.32 million -1.92
Sutro Biopharma Competitors $897.63 million $190.37 million -1.33

Sutro Biopharma’s peers have higher revenue and earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Sutro Biopharma and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sutro Biopharma N/A N/A N/A
Sutro Biopharma Competitors -5,144.22% -64.24% -27.96%

Insider & Institutional Ownership

47.2% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sutro Biopharma and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sutro Biopharma 0 0 4 0 3.00
Sutro Biopharma Competitors 834 2774 6059 261 2.58

Sutro Biopharma presently has a consensus price target of $24.33, suggesting a potential upside of 106.39%. As a group, “Biological products, except diagnostic” companies have a potential upside of 33.44%. Given Sutro Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Sutro Biopharma is more favorable than its peers.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit